BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers by Lee, Y-K et al.
BubR1 as a prognostic marker for recurrence-free survival rates in
epithelial ovarian cancers
Y-K Lee
1,2, E Choi
1, MA Kim
3, P-G Park
1, N-H Park
2 and H Lee*,1
1Department of Biological Sciences and Research Center for Functional Cellulomics, College of Natural Science, Seoul National University, San 56-1,
Shinlim-dong, Gwanak-ku, Seoul 151-742, Republic of Korea;
2Department of Obstetrics and Gynecology, College of Medicine, Seoul National University,
Seoul, Republic of Korea;
3Department of Pathology, College of Medicine, Seoul National University, Seoul, Republic of Korea
BACKGROUND: Epithelial ovarian cancer is one of the most lethal malignancies, and has a high recurrence rate. Thus, prognostic markers
for recurrence are crucial for the care of ovarian cancer. As ovarian cancers frequently exhibit chromosome instability, we aimed at
assessing the prognostic significance of two key mitotic kinases, BubR1 and Aurora A.
METHODS: We analysed paraffin-embedded tissue sections from 160 ovarian cancer patients whose clinical outcomes had been
tracked after first-line treatment.
RESULTS: The median recurrence-free survival in patients with a positive and negative expression of BubR1 was 27 and 83 months,
respectively (Po0.001). A positive BubR1 expression was also associated with advanced stage, serous histology and high grade.
In contrast, Aurora A immunostaining did not correlate with any of the clinical parameters analysed.
CONCLUSION: BubR1, but not Aurora A, is a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.
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Epithelial ovarian cancer is a highly lethal malignancy (Jemal et al,
2007). Although cytoreductive surgery, followed by adjuvant
chemotherapy, enhances clinical responses in the majority of
ovarian cancer patients, many of them experience a recurrence of
disease and eventually die from resistance to chemotherapy
(Kristensen and Trope, 1997). Previous studies have reported
clinicopathological prognostic parameters for ovarian cancer
including stage, grade, remnant of disease, and presence of ascites
(NIH Consensus Conference, 1995). However, these factors have
limitations in that they fail to predict the chances of survival for
individual patients. Biological behaviour of the tumour, response
to chemotherapy, and survival of patients vary even among
clinically similar cases (Friedlander, 1998). Thus, the identification
of individual prognostic factors, such as molecular markers, is
required for predicting disease outcome and choice of treatment.
Chromosome instability (CIN), characterised by aneuploidy and
spontaneous chromosome aberrations, is a hallmark of aggressive
cancers (Sen, 2000). It is noteworthy that aneuploidy is an important
feature in ovarian cancers (But and Gorisek, 2000; Shridhar et al,
2001; Gorringe et al, 2005). Therefore, understanding the basic
mechanisms that lead to aneuploidy in ovarian cancer is crucial in
determining the appropriate course of treatment.
Aneuploidy can result from inaccurate chromosome segrega-
tion, dysregulated centrosome cycles, or improper cytokinesis
(Chi and Jeang, 2007). Therefore, the spindle assembly checkpoint
(SAC), which ensures that all chromosomes are attached to bipolar
spindles and that sister chromatid separation occurs accurately,
has a crucial function in genetic integrity. Impaired SAC function
has been suggested to be one of the causes of aneuploidy in human
cancers (Cahill et al, 1998; Amon, 1999). Among the SAC
components, BubR1 mitotic kinase, known as BUB1B by the
Human Genome Organization, attracts a lot of attention because it
is central in the inhibition of Anaphase promoting complex/
cyclosome (APC/C) (Tang et al, 2001; Yu, 2002; Chan and Yen,
2003; Choi et al, 2009). Furthermore, BubR1 monitors kineto-
chore-microtubule attachments and has a pivotal function in
checkpoint signaling (Abrieu et al, 2000; Lampson and Kapoor,
2005; Elowe et al, 2007).
An accurate centrosome number and organisation is critical in
the equal segregation of chromosomes to daughter cells during
mitosis. Indeed, centrosome aberrations have been observed in
many cancers (Nigg, 2002, 2006). Aurora A kinase is particularly
important for centrosome regulation because it is required for the
maturation of centrosomes during mitosis (Hannak et al, 2001;
Berdnik and Knoblich, 2002). Notably, the overexpression or
amplification of Aurora A kinase has been found to occur in many
human cancers (Zhou et al, 1998; Sen et al, 2002, 2008; Tong et al,
2004), and thus has been suggested to provoke aneuploidy and
tumourigenesis (Sen et al, 2002, 2008; Tong et al, 2004). Although
overexpression of Aurora A is clearly responsible for aneuploidy,
whether it induces carcinogenesis is not clear (Anand et al, 2003;
Zhang et al, 2004; Giet et al, 2005).
In this study, we investigated whether BubR1 or Aurora A levels
can be used as prognostic markers for ovarian cancers.
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sMATERIALS AND METHODS
Cell culture of ovarian cancer cell lines and primary
ovarian cancers
Human ovarian cancer cell lines, OVCAR3, SK-OV-3, and SNU119,
were obtained from the Korean Cell Line Bank and grown in
monolayer cultures in RPMI 1640 supplemented with fetal bovine
serum (10% v/v).
Primary ovarian cancer samples were collected from the Seoul
National University Hospital from patients undergoing cytoreductive
surgery. Tumour tissue was dissected into a 100mm Petri dish
containing serum-free RPMI medium supplemented with trypsin.
After 30min at 371C, the cells were resuspended and maintained in
RPMI 1640 supplemented with fetal bovine serum (10% v/v).
Patients and tissue samples
Tissue specimens for immunohistochemistry were obtained from
160 epithelial ovarian carcinomas by primary cytoreductive surgery
between 1998 and 2005. All samples were taken from primary
ovarian lesions in each patient. The disease stage of each sample was
determined according to the International Federation of Gynecology
and Obstetrics (FIGO) criteria. Of the patients, 82 experienced a
relapse and 37 died of ovarian cancer. Ten normal ovarian tissue
samples were obtained as controls. Formalin-fixed, paraffin-
embedded ovarian carcinoma tissues were used for histological
evaluation. All haematoxylin and eosin (H & E)-stained sections
were reviewed by gynaecological pathologists. The study was
approved by the Institutional Review Board.
Western blot analysis
Protein concentrations were measured with the Bradford protein
assay before analysis. Total cell lysate (30mg of protein) was
separated by SDS–polyacrylamide gel electrophoresis and sub-
jected to western blot analysis. Anti-BubR1 antibody (BD, San Jose,
CA, USA) was used at a dilution of 1:1000 and anti-Aurora A
antibody (Transgenic, Japan) at a dilution of 1:300.
Immunofluorescence analysis
Cells grown on cover slips were fixed with 4% paraformaldehyde,
then permeabilised with 0.5% Triton X-100 phosphate-buffered
saline (0.5% PBS-T). They were then incubated in blocking
solution (20% goat serum in 0.1% PBS–T) and probed with
anti-BubR1 antibody or anti-Aurora A antibodies. The cells were
mounted with Vectashield containing 40,6-diamino-2-phenylindole
(DAPI) (Vector Laboratories, Burlingame, CA, USA). Images were
acquired on the DeltaVision microscope (Applied Precision,
Seattle, WA, USA) as a series of 0.4-mm-thick sections and merged.
Cytogenic analysis
Spreads of metaphases were described previously with slight
modifications (Patel et al, 1998; Lee et al, 1999).
Immunohistochemical analysis
Paraffin blocks from ovarian carcinoma were cut at 4mma d j a c e n tt o
H & E sections. Samples were deparaffinised in xylene, rehydrated
with graded ethanol, and washed in distilled water. The sections were
then placed in 10mM citrate buffer (pH 6.0) and boiled in a
microwave for epitope retrieval. Endogenous peroxidase activity was
quenched by incubating tissue sections in 3% H2O2 for 10min. After
the blocking procedure with 20% goat serum and 1% bovine serum
albumin (BSA) in PBS at room temperature for 1h, sections were
incubated with a primary antibody against BubR1 (mouse mono-
clonal, BD) at a dilution of 1:300 or Aurora A (rabbit polyclonal,
Transgenic) at a dilution of 1:250 in a humidifying chamber at 41C
overnight. They were then washed in PBS for 5min at room
temperature, subsequently stained by the labelled streptavidin biotin
(LSAB) method using a Dako LSAB kit (Dako, Glostrup, Denmark),
and visualised using 3,30-diaminobenzidine. The sections were then
counterstained with haematoxylin.
To check the nuclear staining of Aurora A, antigen retrieval in
20mM Tris–EDTA buffer (pH 9.0) was also performed in 80
samples using antibodies from Novocastra (NCL-L-AK2, New
Castle, UK) at a dilution of 1:50 and following the methods of
Burum-Auensen et al (Burum-Auensen et al, 2007a). The results
were similar to the antigen retrieval procedure using citrate
(pH 6.0) and Tris–EDTA (pH 9.0) buffer described above
(Supplementary Figure). Slides were subjected to the same staining
procedure without the addition of primary antibodies for negative
controls. Microscopic fields from each stained section were
randomly sampled.
In most cases, BubR1 and Aurora A were stained in the
cytoplasm in interphase. However, a few specimens revealed
nuclear staining of Aurora A, especially when Tris–EDTA buffer
(pH 9.0) was used. The percentage of positive staining distribution
was recorded and scored as follows: a score of 0 for staining o5%,
1 for 6–25% staining, 2 for 26–50% staining, 3 for 51–75%
staining, and 4 for staining 475%. The staining intensity was
scored as follows: a score of 0 for absent tumour cell staining, 1 for
weak staining (equivocal to normal epithelium), 2 for moderate
staining, and 3 for strong staining. For BubR1 and Aurora A, the
results for intensity and distribution were summed and total score
was assigned as follows: sum of 0–1, score 0; sum of 2–3, score 1;
sum of 4–5, score 2; sum of 6–7, score 3.
Statistical analysis
The relationships between categorical variables were assessed
using the w
2 test. Recurrence-free survival (RFS) was estimated
using the Kaplan–Meier method, and the differences in survival
were compared using the log-rank test. Multivariate analysis was
carried out using the Cox regression method. A P-value of o0.05
was considered to be statistically significant. Data were analysed
using SPSS software, version 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Aberrant BubR1 and Aurora A levels and subcellular
localisations in ovarian cancer cells
We used western analysis to determine whether the two proteins
are expressed in OVCAR3, SK-OV-3, and SNU119 ovarian cancer
cells. The results show that all three cancer cell lines, which were
randomly picked, express BubR1 and Aurora A to varying degrees
(Figure 1A). As accurate mitosis is guaranteed by the proper
localisation of BubR1 at kinetochores and of Aurora A at
centrosomes, we examined the levels and localisation of BubR1
and Aurora A by immunofluorescence microscopy. As revealed in
Figure 1B, all three cell lines analysed displayed defective Aurora A
or BubR1 immunostaining at appropriate locations. Furthermore,
the patterns of BubR1 and Aurora A staining were heterogeneous
from cell to cell in the same cell line (data not shown).
Chromosome instability is accompanied by a heterogeneity of
chromosome numbers in individual cells. Therefore, cytogenetic
analysis of a statistically significant number of cells is the most
direct measure of assessing aneuploidy. To confirm that these
three cell lines exhibit CIN, we analysed metaphase chromosome
spreads of 10 different cells from each line. The number of
chromosomes in all cancer cell lines (OVCAR3, SK-OV-3,
and SNU119) was highly variable in 10 different metaphase
chromosome spreads (Figure 1C). This result is consistent with
information available from the American Culture Type Collection.
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lines analysed, OVCAR3, exhibited aberrant chromosome fusions,
as well as aneuploidy (Figure 1D).
As immunofluorescence assay (IFA) in ovarian cancer cell lines
depicted a varying degree of BubR1 or Aurora A levels and
subcellular localisation in mitosis (Figure 1B), we next asked
whether primary tumour cells exhibit similar results. The result
showed that the primary tumour cells also displayed mis-
localisations and heterogeneity of BubR1 or Aurora A levels in
IFA (Figure 1E).
Correlation of BubR1 and Aurora A levels and patient
survival
Immunohistochemistry staining was conducted on 170 paraffin-
embedded samples: 160 ovarian cancer and 10 normal ovary
tissues. The age of cancer patients ranged from 18 to 79 years
(median, 51.5 years). Table 1 describes the clinicopathological
characteristics of 160 cancer patients. Except for 10 patients, all the
cancer patients were at stage Ic or higher and hence underwent
primary debulking surgery, followed by taxane and platinum
chemotherapy. Serous cystadenocarcinoma (57.5%) was the most
common histology. Cytoreductive surgery was optimal (p1cm
residual disease) in 51.9%. More than two-thirds of patients had a
complete response to first-line treatment, yet half of them relapsed
(Table 1).
Of the 160 ovarian cancer samples, a quarter of them (24.2%)
were scored 0 for BubR1 immunostaining and about 30% scored 0
for Aurora A, whereas normal specimens scored 0 in all cases
(Table 2, Figure 2). The relationship between levels of BubR1 and
the clinicopathological parameters of 160 tumours is shown in
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Figure 1 Assessing BubR1 and Aurora A levels and localisation in
ovarian cancer cells. (A) Western blot analysis of ovarian cancer cell lines,
OVCAR3, SK-OV-3, and SNU119, using anti-BubR1 and Aurora A
antibodies. (B) Immunofluorescence analysis of ovarian cancer cell lines
(OVCAR3, SK-OV-3, and SNU119). Cells grown on cover slips were fixed
and immunostained with anti-BubR1 (red) and anti-Aurora A (green)
antibodies. DAPI (blue) staining reveals chromosomes. (C) Cytogenic
analysis of ovarian cancer cell lines. Ten different metaphase chromosome
spreads were analysed for their chromosome number. All three ovarian
cancer cell lines are aneuploid. Diploid cells should have 46 chromosomes.
(D) Representative metaphase chromosome spreads showing chromo-
some number aberrations in the three cell lines analysed. In OVCAR3,
chromosome fusions, another important measure of CIN, were observed
in OVCAR3 and are marked as arrows. Scale bars are marked.
(E) Immunofluorescence analysis of three primary ovarian cancer cells
(Ov_ca_01, Ov_ca_02, and Ov_ca_03). Images were taken and processed
on a DeltaVision RT (Applied Precision) with  1000 magnification. White
scale bars 15mm.
Table 1 Clinicopathological characteristics of ovarian cancer patients
Number of patients (%)
Median age (year, range) 51.5 (18–79)
FIGO stage
I 43 (26.9)
II 13 (8.1)
III 86 (53.8)
IV 18 (11.2)
Histology
Serous 92 (57.5)
Mucinous 24 (15.0)
Endometrioid 23 (14.4)
Clear cell 18 (11.2)
Others 3 (1.9)
Grade
1 27 (16.9)
2 43 (26.9)
3 90 (56.2)
Residual tumour
Residual tumour p1cm 83 (51.9)
Residual tumour 41cm 77 (48.1)
Clinical response
Complete response 111 (69.4)
Partial response 16 (10.0)
Stable disease 15 (9.4)
Progressive disease 18 (11.2)
Table 2 Score of BubR1 and Aurora A levels in ovarian tissue samples
Ovarian cancer (n¼160) Normal ovary (n¼10)
BubR1 (%) Aurora A (%) BubR1 (%) Aurora A (%)
Score 0 39 (24.4) 45 (28.1) 10 (100.0) 10 (100.0)
Score 1 60 (37.5) 63 (39.4) 0 0
Score 2 42 (26.3) 36 (22.5) 0 0
Score 3 19 (11.9) 16 (10.0) 0 0
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stage (P¼0.001), serous histology (P¼0.008), high grade
(P¼0.001), and residual tumour (P¼0.021). In contrast, no
significant correlation was observed between the expression of
BubR1 and Aurora A. In univariate survival analysis, BubR1
immunoreactivity was a significant prognostic factor for RFS
(Po0.001), whereas the Aurora A expression was not (P¼0.633).
Patients with immunoreactive BubR1 (score 1, 2, 3) had a median
RFS of 27 months (range, 3–48 months), whereas those with a
negative expression of BubR1 (score 0) had a median RFS of 83
months (range, 2–115 months). Figure 3 shows survival curves
stratified by BubR1 and Aurora A expression. Multivariate survival
analysis (Table 4) indicated that the BubR1 level was an
independent prognostic factor for predicting recurrence of ovarian
cancer patients.
DISCUSSION
Strategies in the treatment of ovarian cancers are mainly
determined by the degree of tumour differentiation, the FIGO
stage of disease, and the volume of residual disease after surgery.
However, owing to a significant degree of tumour heterogeneity,
even in the same prognostic subgroup, the development of new
prognostic markers that can aid in selecting adequate therapy for
individual patients is essential. In this vein, it should be
emphasised that the mechanisms underlying the development of
each cancer vary, and a consideration of the mechanistic
parameters mirroring the different molecular pathways is required
for tailored cancer therapy.
We have confirmed that CIN is prevalent in ovarian cancer cell
lines (Figure 1), consistent with the notion that taxane, the
microtubule poison, has factored to a large extent in the treatment
of ovarian cancers. As the mutations in SAC genes are rare (Cahill
et al, 1998; Imai et al, 1999; Haruki et al, 2001; Hernando et al,
2001; Olesen et al, 2001; Langerod et al, 2003; Yuan et al, 2006), it
seems that examining the levels of SAC proteins may be more
informative. Furthermore, despite the incidence of CIN in ovarian
cancers, the status of SAC proteins such as Bub1, Mad2, Mad1, and
BubR1 had not been satisfactorily addressed (Lee et al, 2004; Fu
et al, 2007). With these notions, we analysed the levels of BubR1
and Aurora A in 170 specimens for their clinical significance. The
Aurora A (–) Aurora A (+)
B
BubR1 (+) BubR1 (–)
A
500 um 500 um
500 um 500 um
50 µm 50 µm
Figure 2 Immunohistochemical staining of BubR1 and Aurora A (A) Representative positive and negative immunohistochemistry images of BubR1 and
Aurora A in paraffin-embedded human cancer samples (magnification  400). (B) Negative controls for antibody staining. Antigens were retrieved with
Tris–EDTA buffer at pH 9.0. IHC was performed without incubation with primary antibodies. Two examples are shown (magnification  400). Images were
taken on an Olympus BX-51 microscope.
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RFS. Moreover, a high level of BubR1 was associated with several
aggressive clinicopathological parameters. These data imply the
possibility that BubR1 may be related to the progression of
epithelial ovarian cancers. Related to our study, an overexpression
of BubR1 has been observed in several human cancers, including
breast, gastric, bladder, kidney, and colorectal carcinomas (Myrie
et al, 2000; Shichiri et al, 2002; Grabsch et al, 2003; Yamamoto
et al, 2007; Pinto et al, 2008). In addition, it has been reported that
the overall pattern of BubR1 localisation, revealed by immunos-
taining, differed between normal and malignant tissues in bladder,
colon, pancreas, and skin cancers (Shin et al, 2003; Yamamoto
et al, 2007; Burum-Auensen et al, 2007b).
Functional BubR1 is crucial for dividing cells, but not for
quiescent cells. Therefore, our results showing that BubR1
elevation is correlated with poor prognosis, cancer aggression,
and RFS may reflect the proliferative capacity of tumour cells. It is
very likely that the expression of BubR1 is elevated in cycling cells
(Burum-Auensen et al, 2007b). Therefore, we speculate that the
elevated level of BubR1 coincides with a high mitotic index. We do
not think that BubR1 elevation initiates tumourigenesis. Instead,
we speculate that mutations in genes responsible for proliferative
cell signaling or in tumour suppressor genes such as BRCA1,
BRCA2, and p53 are likely to take place before the elevation of
BubR1 levels. Continued proliferation will make the cells
susceptible to a high mutation rate, accompanied by massive cell
death. Surviving cells are likely to have higher levels of BubR1
owing to forced proliferation, and at the same time acquire genetic
instability because of accumulated mutations. This will accelerate
the heterogeneity of the tumour, resulting in resistance to
conventional cancer therapy.
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Figure 3 Recurrence-free survival (RFS) using the Kaplan–Meier method in relation to BubR1and Aurora A levels. (A) BubR1 positive immunostaining in
the tumour had poor RFS compared with negative staining (Po0.001). (B) Aurora A scores did not show significant correlation with RFS.
Table 3 Correlation of BubR1 level and clinicopathological parameters
BubR1 expression
Number of patients Negative Positive P-value
Age
o55 years 97 28 69 0.016
X55 years 63 11 52
FIGO stage
Early (I, II) 56 26 30 0.001
Advanced (III, IV) 104 13 91
Histology
Serous 92 13 79 0.008
Non-serous 68 26 42
Grade
1 27 16 11 0.001
2 and 3 133 23 110
Residual tumour
p1cm 83 32 51 0.021
41cm 77 7 70
Table 4 Univariate and multivariate analysis of prognostic factors in
ovarian cancer patients for recurrence-free survival
Univariate
analysis
Multivariate
analysis
P-value P-value RR (95% CI)
Age
o55 years vs X55
years
0.153 0.134 1.506 (0.085–2.261)
FIGO stage
Early (I, II) vs
advanced (III, IV)
o0.001 0.001 4.375 (2.920–6.555)
Histology
Serous vs non-serous o0.001 0.045 0.363 (0.240–0.549)
Grade
1 vs 2 and 3 0.004 0.012 2.269 (1.686–3.053)
Residual tumour
p1cmvs 41cm o0.001 0.006 3.197 (1.905–5.364)
BubR1 expression
Negative vs positive o0.001 0.035 1.929 (1.400–2.656)
CI¼confidence interval; RR¼relative risk.
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cancers contradicts the report that amplification of Aurora A has
been observed in many human cancers. Despite reports that the
overexpression of Aurora A in Rat1 or NIH3T3 cells induces
transformation (Bischoff et al, 1998; Zhou et al, 1998), transgenic
mice overexpressing Aurora A (Zhang et al, 2004) or the
overexpression of Aurora A in normal fibroblasts (Anand et al,
2003) does not induce neoplastic transformation. These seemingly
contradictory results may come from the fact that the immorta-
lised cell lines, such as Rat1 or NIH3T3, used by Bischoff et al
(1998) and Zhou et al (1998), already harbour mutations and are,
therefore, easier to transform. By comparison, Aurora A over-
expression does not induce tumourigenesis in primary fibroblasts
and mice. Thus, our results may correlate with the notion that
amplification of Aurora A may result in CIN, whereas over-
expression by itself does not initiate neoplastic transformation
(Giet et al, 2005). Similarly, BubR1 amplification does not initiate
tumourigenesis, and its amplification has not been reported in
human cancers.
In conclusion, we suggest that BubR1 is a reliable prognostic
marker for predicting RFS after initial treatment, and that
assessing the levels of BubR1 in early-stage ovarian cancer
patients, especially with FIGO I stage, can influence the choice of
adequate treatment for ovarian cancers. Furthermore, modulating
BubR1 activity may be a promising future approach to tailored
therapy for ovarian cancers.
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